GlassScriptPhysician profile
Sabry A Gabriel
NPI 1730288424
$5,920.33
in general payments reported to CMS, 2019-2025
37 companies · $1,547 in 2025
The $1,547 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143 · 2020: $423 · 2021: $178 · 2022: $1,015 · 2023: $985 · 2024: $1,629 · 2025: $1,547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,152 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,151.97 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $842.91 | 2021-2025 | |
| Pfizer INC. | $633.02 | 2021-2025 | |
| Novo Nordisk INC | $605.95 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $487.48 | 2020-2025 | Evenity, Otezla, Repatha |
| Lilly USA, LLC | $484.43 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $368.30 | 2019-2025 | Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $305.20 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $293.96 | 2022-2024 | |
| Allergan, INC. | $264.73 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $171.82 | 2020-2024 | Xifaxan, Trulance |
| Biosense Webster, INC. | $147.73 | 2025 | Carto 3 |
| Astellas Pharma US INC | $133.55 | 2023 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $125.74 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $94.17 | 2023-2025 | Rexulti |
| Glaxosmithkline, LLC. | $94.04 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.69 | 2022-2025 | Jardiance, Synjardy |
| Abbott Laboratories | $75.93 | 2022-2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $72.39 | 2025 | Korlym |
| Merck Sharp & Dohme LLC | $68.23 | 2022-2025 | Verquvo, Gardasil 9, Capvaxive |
| Currax Pharmaceuticals LLC | $59.54 | 2022-2025 | Contrave |
| Ardelyx, INC. | $49.79 | 2024-2025 | Ibsrela |
| Dexcom, INC. | $45.74 | 2023-2024 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $45.35 | 2022-2023 | Krystexxa |
| Lundbeck LLC | $44.82 | 2023-2025 | Vyepti, Rexulti |
| Idorsia Pharmaceuticals US INC | $41.80 | 2023-2024 | Quviviq |
| Novartis Pharmaceuticals Corporation | $39.51 | 2022-2023 | |
| Medtronic, INC. | $36.41 | 2025 | Kyphon Express II Kyphopak Tray |
| Kerecis Limited | $26.58 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Vertex Pharmaceuticals Incorporated | $24.93 | 2025 | |
| Amarin Pharma, INC. | $24.73 | 2022 | |
| Alkermes, INC. | $22.64 | 2025 | Vivitrol |
| Seqirus USA INC | $22.29 | 2025 | Fluad, Flucelvax |
| Medline Industries LP | $18.04 | 2023 | |
| Ibsa Pharma INC. | $17.45 | 2025 | Tirosint, Flector, Licart |
| Esperion Therapeutics, INC. | $16.11 | 2024 | Nexletol |
| Exact Sciences Corporation | $13.29 | 2024 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $11.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sabry Gabriel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.